Accuitis
PrivateLast Round
VC Round
Nov 23, 2015
Company Overview
Accuitis is a pharmaceutical company that develops small molecule compounds validated in preclinical models for neurodegenerative, age-related, and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accuitis Comparables
Compare Accuitis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mitochon Pharmaceuticals | 81% | |
| NRG Therapeutics | 79% | |
| Vandria | 77% | |
Accuitis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 23, 2015 | ||||
| VC Round | Mar 23, 2015 |
Accuitis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Georgia Research Alliance | VC Round |
| Bio/Med Investor Network | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 23, 2015
$1M raised from Bio/Med Investor Network and Georgia Research Alliance.
- Mar 23, 2015
$495K raised from Bio/Med Investor Network and GRA.
Accuitis Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Accuitis's valuation, stock price, and market status.